Literature DB >> 28771772

Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations.

Rokaya El Ansari1, Alan McIntyre2, Madeleine L Craze1, Ian O Ellis1,3, Emad A Rakha1,3, Andrew R Green1.   

Abstract

Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy and cellular building blocks. These metabolic alterations are mediated by many oncogenic changes that affect cellular signalling pathways, which result in sustained cell growth and proliferation. Recently, metabolomics has received great attention in the field of cancer research, and as the essential metabolic pathways that drive tumour growth and progression are determined the possibilities of new targets for therapeutic intervention are opened. More specifically, as breast cancer is a heterogeneous disease, there is growing evidence that differences in metabolic changes exist between molecular subtypes. In this review, the most recent findings in breast cancer cell metabolism are discussed, with particular emphasis on glutamine and its transporters, which is considered one of the key amino acids fuelling cancer growth. Furthermore, the metabolic differences between the molecular subtypes of breast cancer are examined, highlighting the clinical utility for breast cancer diagnosis and treatment.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  breast cancer; glutamine; metabolic pathways; molecular classes

Mesh:

Substances:

Year:  2017        PMID: 28771772     DOI: 10.1111/his.13334

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  20 in total

Review 1.  Metabolism and immunity in breast cancer.

Authors:  Deyu Zhang; Xiaojie Xu; Qinong Ye
Journal:  Front Med       Date:  2020-10-19       Impact factor: 4.592

2.  Comparative stemness and differentiation of luminal and basal breast cancer stem cell type under glutamine-deprivation.

Authors:  Heena Jariyal; Chanchal Gupta; Shambhavi Andhale; Sonali Gadge; Akshay Srivastava
Journal:  J Cell Commun Signal       Date:  2021-01-28       Impact factor: 5.782

3.  A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer.

Authors:  Liping Yan; Jianxin He; Xiwen Liao; Tianyi Liang; Jia Zhu; Wensong Wei; Yongfei He; Xin Zhou; Tao Peng
Journal:  Gland Surg       Date:  2022-02

Review 4.  Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Authors:  Mitra Behroozaghdam; Maryam Dehghani; Amirhossein Zabolian; Davood Kamali; Salar Javanshir; Farzaneh Hasani Sadi; Mehrdad Hashemi; Teimour Tabari; Mohsen Rashidi; Sepideh Mirzaei; Atefeh Zarepour; Ali Zarrabi; Danielle De Greef; Anupam Bishayee
Journal:  Cell Mol Life Sci       Date:  2022-10-04       Impact factor: 9.207

Review 5.  A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response.

Authors:  Marcella Regina Cardoso; Juliana Carvalho Santos; Marcelo Lima Ribeiro; Maria Cecília Ramiro Talarico; Lais Rosa Viana; Sophie Françoise Mauricette Derchain
Journal:  Int J Mol Sci       Date:  2018-02-21       Impact factor: 5.923

Review 6.  Amino Acid Transporters and Glutamine Metabolism in Breast Cancer.

Authors:  Yoon Jin Cha; Eun-Sol Kim; Ja Seung Koo
Journal:  Int J Mol Sci       Date:  2018-03-19       Impact factor: 5.923

7.  The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.

Authors:  Rokaya El Ansari; Madeleine L Craze; Islam Miligy; Maria Diez-Rodriguez; Christopher C Nolan; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Breast Cancer Res       Date:  2018-03-22       Impact factor: 6.466

8.  HIV infection and latency induce a unique metabolic signature in human macrophages.

Authors:  Paul Castellano; Lisa Prevedel; Silvana Valdebenito; Eliseo A Eugenin
Journal:  Sci Rep       Date:  2019-03-08       Impact factor: 4.379

9.  The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer.

Authors:  Soheila Delgir; Khandan Ilkhani; Asma Safi; Yazdan Rahmati; Vahid Montazari; Zahra Zaynali-Khasraghi; Farhad Seif; Milad Bastami; Mohammad Reza Alivand
Journal:  BMC Med Genomics       Date:  2021-07-07       Impact factor: 3.063

10.  The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.

Authors:  Rokaya El Ansari; Lutfi Alfarsi; Madeleine L Craze; Brendah K Masisi; Ian O Ellis; Emad A Rakha; Andrew R Green
Journal:  Breast Cancer Res Treat       Date:  2020-03-21       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.